Foreign institutional investors (FIIs) have acquired over 4 million shares of Ranbaxy Laboratories in the January - March 2014 quarter. They held 10.79% stake in the company in December quarter.
The overseas investors have increased their stake in the company by 1.1 percentage points to 11.79% in Q4, the highest since June 2012 quarter. On the other hand, domestic institutional investors (DII) and bodies corporate have offloaded collectively nearly a two percentage point stake in the company during the quarter. Total DIIs stake in the company declined to 8.30% from 8.81% and of Bodies Corporate to 1.64% from 3.05% earlier.
Orange Mauritius Investments bought 4.55 million shares, representing 1.07% stake, in the pharmaceutical major during the March quarter, as against nil holding in December quarter.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
